HOME >> MEDICINE >> NEWS
Transplant patients keep their new kidney longer with a CellCept-based drug combination

24 July 2006, Basel, Switzerland -- The largest ever comparative transplantation study, involving 1,645 kidney transplant patients, has revealed the best immunosuppressant drug regimen that will give patients a better chance of a normal life. CellCept (mycophenolate mofetil) plus low-dose tacrolimus, corticosteroids and IL-2 induction therapy was shown to be the top combination to prevent patients rejecting their new kidney whilst maximising the function and life of the new organ.

The results at 12 months showed significantly improved kidney function (15%, p<0.0001), up to a further 65% reduction in early rejection and up to 6% improvement in organ survival for patients receiving the CellCept plus low-dose tacrolimus combination. This could mean that, if all first time kidney recipients were to take this regimen, nearly 2,500* organs could be saved in the first year post transplant.

"The results of the SYMPHONY study are an exciting and long-awaited development for both patients and doctors," commented lead investigator, Professor Henrik Ekberg, from University Hospital, Malm, Sweden, following the study's presentation at the World Transplant Congress, Boston. "New immunosuppressant drugs have successfully reduced the rejection rates of the new organ. However, patients still face developing serious side effects from the life long use of some of these drugs. The focus is now to define the optimal balance of these combinations in order to prolong further the life of the patient and their transplanted organ. SYMPHONY now provides the answer for doctors that the best regimen for patients today is CellCept and low dose tacrolimus, steroids and induction therapy."

To prevent rejection of a new kidney by the patient's immune system, immunosuppressant combinations have traditionally contained high dose calcineurin inhibitor's (CNIs), which are now known to cause kidney damage due to toxic side effects. This damage can lead to loss of the n
'"/>

Contact: Helen swift
Helen.Swift@Ketchum.com
44-207-611-3637
Ketchum
24-Jul-2006


Page: 1 2

Related medicine news :

1. Transplanting human gut bugs into mice helps understanding of metabolic system
2. Transplanting organs from animals to humans -- what are the barriers?
3. Childrens surgeon to present results of new anti-rejection protocol at World Transplant Congress
4. Transplantation Report 2005
5. Transplantation of sperm stem cells restores fertility after chemotherapy
6. Transplanting kidneys which have stones poses little risk to organs viability
7. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
8. Comparison of obstetric outcomes between on-call and patients own obstetricians
9. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
10. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
11. Happier hospitals means healthier patients

Post Your Comments:
(Date:5/24/2015)... Metamora, Michigan (PRWEB) May 24, 2015 ... for concerns about hair loss. Although it is unclear ... that there are environmental factors such as metabolism, nutritional ... contribute. Since they offer a comprehensive approach to evaluating ... and post-menopausal woman, they can help patients find a ...
(Date:5/24/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... tests, which will allow them to take pressure measurements ... about bladder function. The doctor usually orders it if ... or overactive bladder (OAB). , Women’s Excellence ... that have problems with unwanted urinary leakage or problems ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 EnviroLeather™ ... launches “InkGard™ Plus” – a classic, rugged leather ... polymer allowing difficult stains, including ink, to be ... different colors suitable for corporate, healthcare, hospitality and ... line with EnviroLeather’s goal of developing products that ...
(Date:5/24/2015)... Viejo, CA (PRWEB) May 24, 2015 ProPin ... use in Final Cut Pro X. Utilize ProPin to pin ... in a given scene. , ProPin allows users to ... completely customizable in FCPX. With on-screen controls, video editors can ... allows users to pin and mark with absolute ease. , Using ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Medicx Media Solutions Expands Executive Team 2
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... the results of the Company,s 72-patient, placebo-controlled Phase ... for the treatment of dry eye patients using ... model.  The exploratory study was completed in late ... by the Company in a press release, identify ...
(Date:5/22/2015)... 20, 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ... "Guide to Prepare Application Dossiers for Oversea Medical ... " report to their offering. ... segment market of the most growth potentiality, which ... manufacturers and producers to penetrate such market. It ...
(Date:5/22/2015)... 2015 Today, Rhodes Pharmaceuticals L.P. announced that ... indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) ... The announcement comes just one ... U.S. Food and Drug Administration (FDA). ... methylphenidate capsule with an onset of effect of ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
Cached News: